5260 related articles for article (PubMed ID: 3756939)
1. Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft.
Osieka R; Glatte P; Pannenbäcker R; Schmidt CG
Cancer Treat Rep; 1986 Oct; 70(10):1167-71. PubMed ID: 3756939
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.
Cohen MH; Schoenfeld D; Wolter J
Cancer Treat Rep; 1980 Jan; 64(1):151-3. PubMed ID: 6991102
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization by chlorpromazine (CPZ) and caffeine (C) in human melanoma xenografts sensitive or resistant to methyl-CCNU (semustine).
Osieka R; Glatte P; Schmidt CG
Strahlenther Onkol; 1989 Jul; 165(7):526-8. PubMed ID: 2749491
[No Abstract] [Full Text] [Related]
4. Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
Rose WC; Trader MW; Dykes DJ; Laster WR; Schabel FM
Cancer Treat Rep; 1978 Dec; 62(12):2085-93. PubMed ID: 751716
[TBL] [Abstract][Full Text] [Related]
5. Nitrosoureas: a review of experimental antitumor activity.
Schabel FM
Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694
[TBL] [Abstract][Full Text] [Related]
6. [Enhancement of MeCCNU potency (chemosensitization) by misonidazole in a human melanoma xenograft system].
Osieka R; Glatte P; Haedecke U; Schmidt CG
Strahlentherapie; 1982 Oct; 158(10):620-9. PubMed ID: 7179344
[TBL] [Abstract][Full Text] [Related]
7. In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome.
Kirkwood JM; Marsh JC
Cancer Res; 1983 Jul; 43(7):3434-40. PubMed ID: 6850650
[TBL] [Abstract][Full Text] [Related]
8. Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
Hill HZ; Hill GJ
Cancer Res; 1982 Mar; 42(3):838-42. PubMed ID: 7059982
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
Osieka R; Glatte P; Pannenbäcker R; Schmidt CG
Cancer Chemother Pharmacol; 1983; 11(3):147-52. PubMed ID: 6227420
[TBL] [Abstract][Full Text] [Related]
10. Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells.
Dempke W; Nehls P; Wandl U; Soll D; Schmidt CG; Osieka R
J Cancer Res Clin Oncol; 1987; 113(4):387-91. PubMed ID: 3597524
[TBL] [Abstract][Full Text] [Related]
11. Inhibition and recovery of DNA synthesis in host tissues and sensitive and resistant B16 melanoma after 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea, a predictor of therapeutic efficacy.
Brereton HD; Bryant TL; Young RC
Cancer Res; 1975 Sep; 35(9):2420-5. PubMed ID: 1149044
[TBL] [Abstract][Full Text] [Related]
12. [Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].
Fischel JL; Barbé V; Berlion M; Formento P; Berrile J; Bizzari JP; Milano G
Bull Cancer; 1994 Jul; 81(7):599-604. PubMed ID: 7742602
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
14. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
Hill HZ; Hill GJ; Miller CL; Pfaller M; Weiss K; Galin M
Cancer Res; 1979 Mar; 39(3):934-9. PubMed ID: 427782
[TBL] [Abstract][Full Text] [Related]
15. Nitrosoureas in the management of disseminated malignant melanoma.
Ahmann DL
Cancer Treat Rep; 1976 Jun; 60(6):747-51. PubMed ID: 782696
[TBL] [Abstract][Full Text] [Related]
16. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of L1210 leukemia using neuraminidase-modified plasma membranes combined with chemotherapy.
Pincus JH; Jameson AK; Brandt AE
Cancer Res; 1981 Aug; 41(8):3082-6. PubMed ID: 7248965
[TBL] [Abstract][Full Text] [Related]
18. Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
Didolkar MS; Baffi RR; Catane R; Kaufman J; Holyoke ED
Cancer Treat Rep; 1977 Dec; 61(9):1738-9. PubMed ID: 597824
[No Abstract] [Full Text] [Related]
19. Human malignant melanoma: preclinical and clinical drug evaluation.
Osieka R
Behring Inst Mitt; 1984 May; (74):353-67. PubMed ID: 6383327
[TBL] [Abstract][Full Text] [Related]
20. [Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
Kokoschka EM; Luger T; Micksche M
Onkologie; 1978 Jun; 1(3):98-103. PubMed ID: 362293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
